CIA-1 (Free base)

CAS No. 452087-38-6

CIA-1 (Free base)( —— )

Catalog No. M36369 CAS No. 452087-38-6

CIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 70 In Stock
10MG 112 In Stock
25MG 226 In Stock
50MG 345 In Stock
100MG 532 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CIA-1 (Free base)
  • Note
    Research use only, not for human use.
  • Brief Description
    CIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines.
  • Description
    CIA-1 (Free base) is a nuclear receptor COUP-TFII inhibitor with IC50 values ranging from 1.2 μM to 7.6 μM in prostate cancer cell lines. CIA-1 (Free base) inhibits tumor growth in a mouse model of prostate cancer xenografts.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    Gamma-secretase
  • Recptor
    Gamma-secretase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    452087-38-6
  • Formula Weight
    329.42
  • Molecular Formula
    C17H19N3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(CCC1=CC(OC)=C(OC)C=C1)C2=C3C(SC(C)=C3)=NC=N2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Enoticumab

    Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.

  • Brontictuzumab

    Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway.

  • PEAQX

    PEAQX(NVP-AAM 077) is an effective and orally available NMDA antagonist. It can inhibit human NMDA receptors for 1A/2A(IC50: 270 nM), rather than 1A/2B(29, 600 nM).